A multicentre validation of Metasin: a molecular assay for the intraoperative assessment of sentinel lymph nodes from breast cancer patients

Treatment strategies for breast cancer continue to evolve. No uniformity exists in the UK for the management of node‐positive breast cancer patients. Most centres continue to use conventional histopathology of sampled sentinel lymph nodes (SLNs), which requires delayed axillary clearance in up to 25% of patients. Some use touch imprint cytology or frozen section for intraoperative testing, although both have inherent sensitivity issues. An intraoperative molecular diagnostic approach helps to overcome some of these limitations. The aim of this study was to assess the clinical effectiveness of Metasin, a molecular method for the intraoperative evaluation of SLNs.

[1]  M. Somerfield,et al.  Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  R. Mújica-Mota,et al.  A systematic review and economic evaluation of intraoperative tests [RD-100i one-step nucleic acid amplification (OSNA) system and Metasin test] for detecting sentinel lymph node metastases in breast cancer. , 2015, Health technology assessment.

[3]  K. Horgan,et al.  Pathological evaluation of the staging axillary lymph nodes for breast cancer: a national survey in the United Kingdom , 2014, Histopathology.

[4]  A. Hanby,et al.  Systematic review and meta‐analysis of cytokeratin 19‐based one‐step nucleic acid amplification versus histopathology for sentinel lymph node assessment in breast cancer , 2014, The British journal of surgery.

[5]  A. Purushotham,et al.  When is a completion axillary lymph node dissection necessary in the presence of a positive sentinel lymph node? , 2014, European journal of cancer.

[6]  G. Cserni.  [Sentinel lymph node status and axillary lymph node dissection in the surgical treatment of breast cancer]. , 2014, Orvosi hetilap.

[7]  R. Salgado,et al.  Metasin—An Intra-Operative RT-qPCR Assay to Detect Metastatic Breast Cancer in Sentinel Lymph Nodes , 2013, International journal of molecular sciences.

[8]  W. Mali,et al.  Preoperative needle biopsy of sentinel lymph nodes using intradermal microbubbles and contrast-enhanced ultrasound in patients with breast cancer. , 2012, AJR. American journal of roentgenology.

[9]  F. Lumachi,et al.  Touch imprint cytology and frozen-section analysis for intraoperative evaluation of sentinel nodes in early breast cancer. , 2012, Anticancer research.

[10]  A. Giuliano,et al.  Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. , 2011, JAMA.

[11]  L. Esserman,et al.  Intraoperative frozen section analysis of sentinel lymph nodes in breast cancer patients , 2011, Cancer.

[12]  M. Mainiero,et al.  Axillary ultrasound and fine-needle aspiration in the preoperative evaluation of the breast cancer patient: an algorithm based on tumor size and lymph node appearance. , 2010, AJR. American journal of roentgenology.

[13]  J. Weeks,et al.  Axillary Ultrasound Assessment in Primary Breast Cancer: An Audit of 653 Cases , 2010, The breast journal.

[14]  J. Raftery,et al.  Observational and cost analysis of the implementation of breast cancer sentinel node intraoperative molecular diagnosis , 2010, Journal of Clinical Pathology.

[15]  Chiu-Hsieh Hsu,et al.  Intraoperative Touch Imprint and Frozen Section Analysis of Sentinel Lymph Nodes After Neoadjuvant Chemotherapy for Breast Cancer , 2010, Annals of surgery.

[16]  D. Larsimont,et al.  Clinical validation of a molecular assay for intra-operative detection of metastases in breast sentinel lymph nodes. , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[17]  D. Rew.  The challenges of success. , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[18]  Surgical guidelines for the management of breast cancer. , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[19]  R. Newcombe,et al.  Detection of breast cancer metastasis in sentinel lymph nodes using intra-operative real time GeneSearch™ BLN Assay in the operating room: results of the Cardiff study , 2009, Breast Cancer Research and Treatment.

[20]  R. Mansel,et al.  Injection of radioactive colloid and blue dye at the peri-areolar edge in the tumor quadrant for sentinel lymph node biopsy in breast cancer: Results of the UK NEW START training program , 2008 .

[21]  G. Viale,et al.  Comparative Evaluation of an Extensive Histopathologic Examination and a Real-Time Reverse-Transcription-Polymerase Chain Reaction Assay for Mammaglobin and Cytokeratin 19 on Axillary Sentinel Lymph Nodes of Breast Carcinoma Patients , 2008, Annals of surgery.

[22]  R. Simmons,et al.  Scientific Impact Recognition Award. Sentinel node staging for breast cancer: intraoperative molecular pathology overcomes conventional histologic sampling errors. , 2007, American Journal of Surgery.

[23]  H. Tsuda,et al.  One-step Nucleic Acid Amplification for Intraoperative Detection of Lymph Node Metastasis in Breast Cancer Patients , 2007, Clinical Cancer Research.

[24]  F. MacNeill.  NEW START : the UK SLNB training programme -a progress report , 2007 .

[25]  U. Chetty,et al.  Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. , 2006, Journal of the National Cancer Institute.

[26]  L. Irwig,et al.  Meta‐analysis of sentinel node imprint cytology in breast cancer , 2005, The British journal of surgery.

[27]  Yixin Wang,et al.  Identification and characterization of optimal gene expression markers for detection of breast cancer metastasis. , 2005, The Journal of molecular diagnostics : JMD.

[28]  Qinghua Feng,et al.  Mammaglobin as a novel breast cancer biomarker: multigene reverse transcription-PCR assay and sandwich ELISA. , 2004, Clinical chemistry.

[29]  R. Newcombe,et al.  Predictors of non-sentinel lymph node metastasis in breast cancer patients. , 2004, European journal of cancer.

[30]  J. Peterse,et al.  Discrepancies in current practice of pathological evaluation of sentinel lymph nodes in breast cancer. Results of a questionnaire based survey by the European Working Group for Breast Screening Pathology , 2004, Journal of Clinical Pathology.

[31]  D. Carter,et al.  Mammaglobin: a candidate diagnostic marker for breast cancer. , 2004, Clinical biochemistry.

[32]  S. Singletary,et al.  Revision of breast cancer staging: the 6th edition of the TNM Classification. , 2003, Seminars in surgical oncology.

[33]  S. Reed,et al.  Application of a multigene reverse transcription-PCR assay for detection of mammaglobin and complementary transcribed genes in breast cancer lymph nodes. , 2002, Clinical chemistry.

[34]  A. Luini,et al.  Intraoperative examination of axillary sentinel lymph nodes in breast carcinoma patients , 1999, Cancer.

[35]  A. Luini,et al.  Sentinel lymph node biopsy and axillary dissection in breast cancer: results in a large series. , 1999, Journal of the National Cancer Institute.

[36]  Umberto Veronesi,et al.  Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes , 1997, The Lancet.

[37]  E. Lane,et al.  Expression of cytokeratin messenger RNA versus protein in the normal mammary gland and in breast cancer. , 1996, Human pathology.

[38]  A. Giuliano,et al.  Improved Axillary Staging of Breast Cancer with Sentinel Lymphadenectomy , 1995, Annals of surgery.